Organon, a global healthcare company focused on women’s health, has entered into an agreement to acquire Dermavant for up to $1.2 billion. The acquisition aims to improve women’s health by investing in treatments for conditions that affect women differently. The agreement includes Dermavant’s product, Vtama cream 1%, for plaque psoriasis, with potential FDA approval for atopic dermatitis. Organon will pay upfront, milestone payments, and royalties to Dermavant shareholders. The companies expect to close the transaction in the fourth quarter of 2024. Kevin Ali, CEO of Organon, expressed excitement about the acquisition and the potential for combining resources to deliver better healthcare solutions for women.
Source link
Organon to acquire Dermavant, Vtama cream in definitive agreement
